Oktey has been acquired by Vincent Saint-Martin and Ciclad
Stéphane Manhes and other shareholders of Oktey Altospam have sold the company to Vincent Saint-Martin.
Oktey Altospam is an integrated SaaS B2B services provider, protecting email accounts from spam, viruses, scams and phishing. The firm allows companies that own at least one domain name to secure its email servers. It combines 16 anti-spam technologies and six anti-viruses, as well as other security services such as anti-relay, anti-scam, anti-phishing and protection against denial-of-service attacks. The company generates over US$2 million ARR, with steady growth over the years of 5–6%.
Vincent Saint-Martin is a French entrepreneur involved in several digital projects. He is the founder of Unevoiturealouer, which then became Ouicar, and which he significantly developed over the years. Ouicar has recently been sold to American peer-to-peer car-sharing company Turo. Vincent Saint-Martin is supported by French private equity group Ciclad.
Oaklins’ team in France acted as financial advisor to the founder and other shareholders of Oktey throughout a highly competitive sale process to structure the most attractive transaction.



Stéphane Manhes
Founder, Oktey Altospam
Talk to the deal team
Related deals
STM Environmental has been acquired by Phenna Group
STM Environmental has been acquired by Phenna Group, gaining access to a broader network of expertise, enhanced resources and global reach. With extensive experience in life safety, environmental compliance and quality testing, along with a wide client base, Phenna Group is the ideal partner to accelerate STM Environmental’s expansion.
Learn moreDen Berk Délice accelerates growth through strategic partnership
Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more